Moreover, it was recently demonstrated that CK2 and IKZF1 regulate chemoresistance to doxorubicin via repression of BCL2L1 (BCL-XL) and a combination treatment involving a CK2 inhibitor and doxorubicin has a synergistic therapeutic effect on high-risk B-ALL in vivo [24]. Here, IKZF1 is linked to precursor B-cell acute lymphoblastic leukemia.